Full-Time

Computational Scientist

Protein Library Design

Confirmed live in the last 24 hours

Manifold Bio

Manifold Bio

11-50 employees

Designs precision biologics using in vivo methods

Biotechnology
Healthcare

Mid, Senior

Boston, MA, USA

Category
Bioinformatics
Computational Biology
Biology & Biotech
Required Skills
Python
Data Structures & Algorithms
Linux/Unix
Data Analysis
Requirements
  • PhD and/or 4+ years of equivalent experience in computational biology, bioinformatics, genomics, systems/synthetic biology, protein engineering, or a similar field working with biological sequences or systems; wet lab experience is a plus
  • First-hand experience with any of the following: DNA/Protein sequence analysis, computational protein design, probabilistic modeling, machine learning, biophysical modeling, or antibody design
  • Experience with the design and analysis of massively parallel reporter assays (MPRAs)
  • Experience designing DNA libraries for binders, DMS, or equivalent high-throughput experiments
  • Experience working with Next Generation Sequencing (NGS) data
  • Strong understanding of statistics fundamentals
  • Fluency in one or more programming languages, Python preferred
  • Basic familiarity with version control, test-driven development, and Unix computing
  • Ability to meet the demands of multiple concurrent projects in a fast-paced research environment
  • Outstanding written and verbal communication skills
  • A deep passion for science and developing new methods
Responsibilities
  • Work closely with Manifold’s scientific teams to design maximally informative protein libraries
  • Collaborate on designing high-throughput experiments and analyze/interpret results
  • Perform data analysis to identify patterns in the mapping from sequence to function
  • Create tools, algorithms, models, and data pipelines to support our Compute and experimental teams
  • Proactively share your findings with colleagues through high-quality documentation and discussions

Manifold Bio specializes in creating precision biologics for the pharmaceutical industry, focusing on drug design and development. Their main product is an in vivo drug design platform, which allows for testing drugs within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment, making it particularly effective for complex biologics. Unlike other companies, Manifold Bio's approach is distinguished by its ability to conduct these tests in a pooled in vivo environment. The company's goal is to expand its drug design platform and collaborate with other pharmaceutical companies to develop new therapeutics.

Company Stage

Series A

Total Funding

$58.8M

Headquarters

Boston, Massachusetts

Founded

2020

Growth & Insights
Headcount

6 month growth

-9%

1 year growth

-2%

2 year growth

48%
Simplify Jobs

Simplify's Take

What believers are saying

  • The significant Series A funding provides ample resources for expanding their in vivo biologics design platform, potentially accelerating growth and innovation.
  • Manifold Bio's technology could revolutionize the drug discovery process by overcoming the bottleneck of in vivo testing, making it more efficient and cost-effective.
  • Partnerships and collaborations with other pharmaceutical companies could lead to lucrative licensing deals and revenue streams.

What critics are saying

  • The highly specialized nature of their technology may limit their market to a niche segment within the pharmaceutical industry.
  • Dependence on successful integration and performance of their mCodes™ technology in real-world applications could pose a risk if the technology does not meet expectations.

What makes Manifold Bio unique

  • Manifold Bio's in vivo drug design platform, powered by their proprietary mCodes™ technology, allows for simultaneous testing of multiple proteins in a single experiment, a unique capability in the pharmaceutical industry.
  • Their focus on precision biologics and complex biologics sets them apart from competitors who may not specialize in these advanced therapeutic areas.
  • The recent $40 million Series A funding round underscores strong market interest and confidence in their innovative approach to drug development.

Help us improve and share your feedback! Did you find this helpful?